Aung Pyae Phyo

Aung Pyae Phyo, a Burmese (Myanmar) Senior Clinican Scientist, finished medical training in 2001 in Yangon. He joined the Shoklo Malaria Research Unit in 2005 where he has led the cohort which unearthed the emergence of artemisinins resistance on the Thai-Myanmar border in 2010.

Afterwards, he pursued research on the Artemisinin Combination Therapy resistant malaria as well as the trials on the new antimalarial compounds such as OZ439 (Artefenomel), KAF156 (Ganaplacide) and KAE609 (Cipargamin).

In 2017 Aung Pyae Phyo completed his Doctor of Philosophy in Clinical Medicine at Oxford University. After completing the DPhil, he joined the Myanmar Oxford Clinical Research Unit in Yangon, Myanmar where his focus is malaria elimination and surveillance of the spread of drug resistant malaria in Greater Mekong Subregion (GMS).

In 2019 Aung Pyae Phyo received post-doctoral International Training fellowship from the Wellcome Trust to assess the immune decay after malaria elimination and the risk of malaria resurgence, and a seed grant from Australian Centre of Research Excellence in Malaria Elimination (ACREME) for the project Field evaluation of a point-of-contact device for P. falciparum malaria sero-surveillance